Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Emerging Company Profile

Alltrna: Creating the tRNA modality

Flagship’s latest RNA company Alltrna aims to pioneer tRNA therapies

November 9, 2021 3:19 PM UTC

Flagship-launched Alltrna is building on recent mRNA momentum with a platform designed to uncover the therapeutic potential of another type of RNA — tRNA — and turn it into an entirely new therapeutic modality.

The company was launched under Flagship Pioneering’s incubation model with $50 million in committed capital from the VC and a plan to develop therapeutics that alter protein expression at the final step of the synthesis process. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article